Massachusetts’ Medicaid program, MassHealth, has inked a conditional deal for Novartis’ $2 million one-time spinal muscular atrophy (SMA) gene therapy, Zolgensma, WBUR reports.
According to the report, MassHealth says it agrees to pay for the drug on the condition it works.
“We think it makes sense to pay for innovation for a drug that could really work,” MassHealth Director Dan Tsai tells WBUR. “And we think the Commonwealth, with public dollars, should not pay for something if it doesn’t do what it’s advertised to do.”
To read more on WBUR, click here.